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Abstract
Objective Several single-nucleotide polymorphisms have been identified to be disadvantageous or protective in regard to 
disease severity in patients with non-alcoholic fatty liver disease (NAFLD). However, it is unclear, whether including genetic 
risk factor(s) either alone or combined into risk stratification algorithms for NAFLD actually provides incremental benefit 
over clinical risk factors.
Design Patients with biopsy-proven NAFLD were genotyped for the PNPLA3-rs738409(minor allele:G), TM6SF2-
rs58542926(minor allele:T) and HSD17B13- rs72613567 (minor allele:TA) variants. The NAFLD activity score (NAS) 
and fibrosis stage (F0–F4) were used to grade and stage all liver biopsy samples. Patients from seven centers throughout 
Central Europe were considered for the study.
Results 703 patients were included: NAS ≥ 5:173(24.6%); Fibrosis: F3–4:81(11.5%). PNPLA3 G/G genotype was associ-
ated with a NAS ≥ 5(aOR 2.23, p = 0.007) and advanced fibrosis (aOR-3.48, p < 0.001).TM6SF2 T/- was associated with 
advanced fibrosis (aOR 1.99, p = 0.023). HSD17B13 TA/- was associated with a lower probability of NAS ≥ 5(TA/T: aOR 
0.65, p = 0.041, TA/TA: aOR 0.40, p = 0.033). Regarding the predictive capability for NAS ≥ 5, well-known risk factors (age, 
sex, BMI, diabetes, and ALT; baseline model) had an AUC of 0.758, Addition of PNPLA3(AUC 0.766), HSB17B13(AUC 
0.766), and their combination(AUC 0.775), but not of TM6SF2(AUC 0.762), resulted in a higher diagnostic accuracy of the 
model. Addition of genetic markers for the prediction of advanced fibrosis (baseline model: age, sex, BMI, diabetes: AUC 
0.777) resulted in a higher AUC if PNPLA3(AUC 0.789), and TM6SF2(AUC 0.786) but not if HSD17B13(0.777) were added.
Conclusion In biopsy-proven NAFLD, PNPLA3 G/-, TM6SF2 T/- and HSD17B13 TA/- carriage are associated with severity 
of NAFLD. Incorporating these genetic risk factors into risk stratification models might improve their predictive accuracy 
for severity of NAFLD and/or advanced fibrosis on liver biopsy.
Keywords NAFLD · Genetic risk factors · NASH · PNPLA3 · TM6SF2 · HSD17B13 · Fibrosis · Advanced fibrosis · Liver 
biopsy · Cirrhosis
Introduction
In recent years, several genetic risk factors associated 
with the susceptibility to and progression of chronic liver 
disease have been identified [1]. Especially in non-alco-
holic fatty liver disease (NAFLD), several genome-wide 
association studies identified sequence variations in the 
genes encoding the patatin-like phospholipase domain-
containing protein 3 (PNPLA3) [2, 3] and transmembrane 
6 superfamily member 2 (TM6SF2) [4, 5] as risk factors 
for progressive NAFLD and hepatocellular carcinoma on 
this background [6]. A variant in the 17B-hydroxysteroid 
dehydrogenase 13 (HSD17B13) gene has been reported to 
protect against NAFLD, progression from hepatic steatosis 
to steatohepatitis (NASH), alcoholic liver disease (ALD), 
and associated liver fibrosis/cirrhosis [7]. Similar obser-
vations were reported in patients with hepatitis C virus 
infection [8], with alcoholic liver disease [9], and with 
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Wilson disease [10]. Furthermore, a study evaluating the 
combined effect of PNPLA3 and TM6SF2 polymorphisms 
in NAFLD found variants of PNPLA3 and TM6SF2 to be 
independently associated with hepatic steatosis, while 
PNPLA3 but not TM6SF2 was associated with liver fibro-
sis in a multivariable model. These findings suggest com-
bined disease-modifying effects of these polymorphisms 
[11].
The aim of our study was to investigate the effects of com-
bining the risk factors PNPLA3, TM6SF2 and HSD17B13 
on severity of NAFLD/NASH in a large cohort of patients 
from seven Central European tertiary care medical centers. 
Furthermore, we investigated if the addition of combined 
genetic factors to well-known risk factors for NAFLD/
NASH increases their predictive value.
Methods
Patients
Patients with biopsy-proven non-alcoholic fatty liver dis-
ease (NAFLD) from tertiary care medical centers in Aus-
tria (Vienna, Oberndorf, Salzburg), Switzerland (Bern) 
and Germany (Dresden, Kiel, Essen) were included in the 
study. Standard laboratory markers and detailed informa-
tion including but not limited to age, height, weight, gender, 
comorbidities (e.g., diabetes) were recorded at the day of 
study inclusion. Patients were referred to the respective ter-
tiary care centers with the suspicion of NAFLD (by either 
steatosis on ultrasound, elevated liver enzymes, presence of 
metabolic syndrome) and have then undergone confirma-
tory liver biopsy. Only patients with histologically confirmed 
NAFLD, graded via the NAFLD activity score (see section 
“Liver biopsy”), were then included in the study. No patient 
without liver biopsy was included in the study. Alcohol con-
sumption was examined by self-reporting; subjects with an 
average alcohol consumption of more than 30 g/day (in men) 
or 20 g/day (in women) were excluded from further evalua-
tion. Patients with other causes of chronic liver disease (i.e., 
autoimmune hepatitis, PSC/PBC, Wilson Disease, Hemo-
chromatosis) were all excluded from the study. Patients with 
active viral hepatitis (HBs-Antigen positivity, detectable 
HBV-DNA, detectable HCV-RNA) were also excluded from 
the study—however, Anti-HBc- or Anti-HCV-Antibody-pos-
itive patients were included if their biopsy results clearly 
stated NAFLD as the primary cause of their liver disease.
Further exclusion criteria were: incomplete or missing 
liver biopsy results, missing blood samples for genotyping, 
and missing informed consent. Finally, seven hundred and 
three patients were included in the study.
Liver biopsy
Percutaneous liver biopsies were obtained in all patients 
using a Menghini needle (Hepafix, B. Braun Melsungen, 
Melsungen, Germany) within clinical routine for diag-
nostic reasons. Biopsy samples were routinely processed 
(formalin fixed and paraffin embedded) and stained with 
hematoxylin/eosin and chromatrope aniline blue for 
assessment of hepatic steatosis, liver fibrosis, and hepatic 
inflammation.
Hepatic steatosis was graded according to Brunt et al. 
[14] using a three-point scale by calculating the percent-
age of lipid containing hepatocytes at a 40 × magnification: 
mild (G1: 5–33%), moderate (G2: 34–66%), or severe stea-
tosis (G3: > 66%). According to the study design, patients 
with less than 5% of fat containing hepatocytes (G0) were 
excluded from our analysis. Hepatocyte ballooning was 
graded as absent (0), rare (1), or prominent ballooning (2). 
Necro-inflammatory activity was graded as absent (0), mild 
(1), moderate (2), or severe (3). The NAFLD activity score 
(NAS) [12, 13] was calculated as the sum of steatosis (1–3), 
hepatocyte ballooning (0–2), and inflammation (0–3) as a 
score from 1 to 8. Liver fibrosis was staged on a five-point 
scale: no fibrosis (stage 0), pericellular fibrosis (stage 1), 
pericellular and portal fibrosis (stage 2), bridging fibro-
sis (stage 3), or cirrhosis (stage 4) [12]. Since severity of 
NAFLD is mostly characterized by the presence/absence 
of steatohepatitis, we defined “severe NAFLD” as patients 
having a NAS ≥ 5 according to studies showing excellent 
discriminative value for this cutoff for the presence of defi-
nite NASH [12, 13].
Genotyping
HSD17B13-rs72613567, PNPLA3-rs738409 and TM6SF2-
rs58542926 genotyping was performed by StepOnePlus 
Real-Time PCR System and a TaqMan SNP Genotyping 
Assay (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Please refer to the supplemental material for a detailed 
description of the statistics used in this manuscript.
Ethics
The study was approved by the ethics committee of the 
Medical University of Vienna (EK 747/2011) and the local 
ethics committees of the participating centers and performed 
in accordance with the current version of the Helsinki 
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Declaration. All patients signed an informed consent form 
prior to study inclusion.
Results
Within the 703 included patients with biopsy-proven 
NAFLD, distribution of NAS was as follows: NAS 1–2—
328 (46.7%), NAS 3–4—202 (28.7%) and NAS ≥ 5—173 
(24.6%). Advanced fibrosis (fibrosis stage 3 or 4) was present 
in 81 (11.5%) and cirrhosis (F4) in 29 (4.1%) of patients. For 
further patient characteristics, see Supplementary Table 1.
PNPLA3 and severity of non‑alcoholic fatty liver 
disease
Carriage of at least one G-allele was associated with a 
more severe phenotype in regard to NAS and presence of 
advanced fibrosis (Supplementary Table S1). G-allele car-
riers were more often found to have a NAS ≥ 5 (G/G: 33 
[42.3%] vs. C/G 75 [28.1%] vs. C/C 65 [18.2%], p < 0.001) 
and severe steatosis (grade 3: G/−: 118 [34.2%] vs. C/C: 64 
[17.9%], p < 0.001). Grade 2 ballooning was significantly 
more often seen in G-allele carriers (G/−: 60 [17.4%] vs. 
C/C: 37 [10.3%], p = 0.007), while severity of inflamma-
tion was not different between G-allele carriers and C/C 
genotypes (p = 0.676). Advanced fibrosis was significantly 
more common in G-allele carriers (G/−: 50 [14.5%] vs. C/C: 
31 [8.7%], p = 0.015) with G/G-carriers having the high-
est prevalence (G/G: 24.4% vs. C/G: 11.6% vs. C/C: 8.7%, 
Supplemental Table S1). Both median AST (p < 0.001) and 
ALT (p < 0.001) were significantly higher in G-allele carri-
ers (Supplementary Table S1).
Multivariable binary logistic regression analysis found 
PNPLA3 G/G carriage associated with NAS ≥ 5 (aOR: 2.23, 
p = 0.007) and F ≥ 3 (aOR: 3.48, p < 0.001) independent of 
presence of diabetes, ALT and gender (for NAS ≥ 5) and 
of age and presence of diabetes (for F ≥ 3; for aORs see 
Tables 1A and 2A).
TM6SF2 and severity of non‑alcoholic fatty liver 
disease
Absolute numbers of T-allele carriers were quite low 
(n = 115 [16%]). The severity of steatosis (percent hepato-
cytes with lipid accumulation) was significantly higher in 
T-allele carriers (p < 0.001, Supplementary Table S2). Nei-
ther ballooning nor inflammation grade differed between 
C/C and T/− allele carriers. However, advanced fibrosis 
was significantly more often found in T/− carriers (T/−: 
20 [17.4%] vs. C/C: 61 [10.4%], p = 0.031). Finally, both 
median AST (p = 0.040) and ALT (p = 0.034) levels were 
higher in T/− carriers (Supplementary Table S2).
Multivariable binary logistic regression analysis found 
TM6SF2 T/− allele carriage associated with advanced fibro-
sis (aOR: 1.99, p = 0.023) independent of age, BMI and dia-
betes mellitus (see Table 2B for aORs). While T-Allele car-
riage was associated with NAS ≥ 5 in univariable analysis 
(OR 1.58, p = 0.041), this effect was not seen after adjusting 
for other variables in the multivariable model (aOR: 1.51, 
p = 0.091; Tables 1B and 2B).
HSD17B13 and severity of non‑alcoholic fatty liver 
disease
Significantly less TA-allele carriers were found with 
NAS ≥ 5 (TA/TA 8 [14.5% [vs. TA/T 52 [20.8%] vs. T/T 
113 [28.4%], p = 0.018; Supplementary Table S3). No sta-
tistical difference was seen in respect to degree of steato-
sis (p = 0.424), inflammation (p = 0.127) or ballooning 
(p = 0.123) for patients carrying the protective HSD17B13 
TA/− variant. TA-allele carriage was not associated with a 
milder phenotype in regard to presence of advanced fibro-
sis (TA/−: 31 [10.2%] vs. T/T: 50 [12.6%], p = 0.324) or 
cirrhosis (TA/−: 10 [3.3%] vs. T/T: 19 [4.8%], p = 0.323; 
Supplementary Table S3).
Multivariable binary logistic regression analysis revealed 
both T/TA and TA/TA genotypes associated with a lower 
probability of NAS ≥ 5 (T/TA aOR: 0.65, p = 0.041, TA/TA 
aOR: 0.40, p = 0.033) independent of gender, diabetes and 
ALT (for aORs see Table 1C). TA-Allele carriage was, how-
ever, not associated with a lower probability for advanced 
fibrosis (Table 2C).
Combination effects of PNPLA3, TM6SF2 
and HSD17B13 on disease severity
To test single- and combined effects of each genetic poly-
morphism on disease severity at clinical presentation, we 
performed a stepwise approach to elucidate whether the 
addition of single/combined genetic markers improve diag-
nostic performance. Clinical endpoints were either presence 
of NAS ≥ 5 (model 1), advanced fibrosis (F3/4) (model 2) 
or significant fibrosis (F ≥ 2) (model 3). The evidence of 
NASH on liver biopsy (≥ NAS 5) “baseline model” included 
age, sex, BMI, diabetes, and ALT. The advanced/signifi-
cant fibrosis “baseline model” included age, sex, BMI, and 
diabetes.
In regard to prediction of NAS ≥ 5 on liver biopsy, the 
AUC of the baseline model was 0.758 (Fig. 1). Addition of 
PNPLA3 (AUC 0.766, p = 0.005 vs. BL) and HSD17B13 
(AUC 0.766, p = 0.005 vs. BL) genotypes resulted in 
improved AUC. In contrast, addition of TM6SF2 to BL did 
not improve AUC (AUC 0.762, p = 0.198). Finally, addi-
tion of both PNPLA3 and HSD17B13 resulted in the highest 
diagnostic accuracy (AUC 0.775) and this was significantly 
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better compared to the PNPLA3 model alone (p = 0.004; 
Fig. 1).
The AUC using the baseline (BL) model for advanced 
fibrosis was 0.778 (Fig. 2). Addition of PNPLA3 (AUC 
0.789, p = 0.001 vs. BL), TM6SF2 (0.786, p = 0.041 vs. 
BL) but not HSD17B13 (AUC 0.777, p = 0.696 vs. BL) 
resulted in a higher diagnostic AUC. Finally, addition of 
both PNPLA3- and TM6SF2 genotypes to the BL model did 
not significantly improve the AUC (AUC 0.79, p = 0.544), 
when compared to the best model including only one genetic 
risk factor (PNPLA3 model).
Prediction of significant fibrosis (F ≥ 2) showed an AUC 
of 0.76 for the baseline model (Supplemental Figure S4). 
Only addition of PNPLA3 status significantly improved the 
model (AUC 0.774, p = 0.001).
Finally, to further investigate the risk-allele approach 
we analyzed clinical markers of disease severity in patients 
stratified according to the number of risk alleles carried. 
Here, we found that prevalence of NAS ≥ 5, severe stea-
tosis, ballooning and presence of advanced or significant 
fibrosis and even cirrhosis significantly increased in an 
“allele dose”-dependent manner (Tables 1D, 2D, 3 and 
Table 1  Uni- and multivariable 
binary regression analyses of 
clinical and laboratory markers 
associated with NAS ≥ 5 on 
liver biopsy and adjusted 
for (A) PNPLA3 genotype, 
(B) TM6SF2 genotype, (C) 
HSD17B13 genotype and 
(D) “risk-allele” model (one 
point for each risk allele, e.g., 
PNPLA3 G-Allele, TM6SF2 
T-Allele, HSD17B13 T-Allele; 
groups “no risk alleles” and “1 
risk allele” have been subsumed 
into one group; to overcome 
potential effects of dilution by 




T-Allele carriage was classified 
as the “risk allele” [rather 
than TA-Allele carriage as 
“protective”] for the combined 
“risk-allele” model)
Univariable Multivariable
OR 95%CI p-value aOR 95%CI p-value
A
Age, per year 1.00 0.99–1.02 0.529 1.00 0.99–1.02 0.660
Sex, for being male 1.03 0.73–1.46 0.848 0.57 0.38–0.86 0.007
BMI, per unit 0.98 0.96–0.99 0.002 0.99 0.98–1.01 0.490
Diabetes, yes vs. no 1.66 1.16–2.37 0.005 1.76 1.17–2.67 0.007
ALT, per unit 1.02 1.02–1.03  < 0.001 1.02 1.02–1.03  < 0.001
PNPLA3 genotype
 C/C vs. C/G 1.76 1.21–2.57 0.003 1.45 0.96–2.19 0.075
 G/G 3.31 1.96–5.58  < 0.001 2.23 1.25–3.99 0.007
B
Age, per year – – – 1.00 0.98–1.02 0.690
Sex, for being male – – – 0.55 0.37–0.83 0.004
BMI, per unit – – – 0.99 0.97–1.01 0.402
Diabetes, yes vs. no – – – 1.79 1.19–2.70 0.005
ALT, per unit – – – 1.02 1.02–1.03  < 0.001
TM6SF2 genotype
 C/C vs. T/– 1.58 1.02–2.44 0.041 1.51 0.94–2.44 0.091
C
Age, per year – – – 1.00 0.99–1.02 0.860
Sex, for being male – – – 0.57 0.38–0.86 0.007
BMI, per unit – – – 0.99 0.97–1.01 0.406
Diabetes, yes vs. no – – – 1.80 1.19–2.72 0.005
ALT, per unit – – – 1.02 1.02–1.03  < 0.001
HSD17B13 genotype
 T/T vs. T/TA 0.66 0.46–0.96 0.031 0.65 0.43–0.98 0.041
 TA/TA 0.43 0.20–0.94 0.034 0.40 0.17–0.93 0.033
D
Age, per year – – – 1.00 0.98–1.02 0.702
Sex, for being male – – – 0.57 0.38–0.87 0.009
BMI, per unit – – – 0.99 0.97–1.02 0.666
Diabetes, yes vs. no – – – 1.79 1.18–2.72 0.007
ALT, per unit – – – 1.02 1.02–1.03  < 0.001
Risk Alleles (Number of)
 0–1 Alleles vs. 2 2.19 1.24–3.86 0.007 2.22 1.19–4.11 0.012
 3 3.53 1.98–6.31  < 0.001 3.42 1.81–6.46  < 0.001
 4 5.65 2.83–11.23  < 0.001 4.65 2.17–9.95  < 0.001
 5 5.11 1.63–16.04 0.005 3.24 0.85–12.29 0.084
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Fig. 3). Furthermore, multivariable binary logistic regres-
sion analysis found the “risk-allele” model associated with 
NAS ≥ 5 and advanced fibrosis (F ≥ 3) independent of gen-
der, diabetes and ALT (for NAS ≥ 5) and age and diabetes 
(for F ≥ 3) also in an “allele dose”-dependent manner (refer 
to Tables 1D and 2D for adjusted ORs).
Discussion
In this study, we analyzed the impact of combined genetic 
variants in PNPLA3, TM6SF2 and HSD17B13 on severity 
and phenotype of NAFLD/NASH in a large multi-center 
cohort of patients with biopsy-proven NAFLD.
First, we confirmed that harboring at least one PNPLA3 
G-allele was associated with a more advanced phenotype in 
regard to both presence of NAS ≥ 5 and advanced fibrosis 
on liver biopsy. TM6SF2 T-allele carriage, even though the 
absolute number of T-allele carriers was low, was also asso-
ciated with a more severe phenotype in regard to advanced 
fibrosis. Conversely, HSD17B13 TA/- allele carriage was 
associated with a milder NAFLD phenotype.
Second, we could show that combining all three genetic 
variants to a “risk-allele” model was associated with a higher 
probability for NAS ≥ 5 and advanced fibrosis in an allele-
dose-dependent manner—meaning the more risk alleles, the 
higher the risk for severe NAFLD/NASH at diagnosis.
Thirdly, we found that addition of PNPLA3 and 
HSD17B13 genotypes, alone and in combination, to 
Table 2  Uni- and multivariable 
binary regression analyses 
of clinical and laboratory 
markers associated with F ≥ 3 
on liver biopsy and adjusted 
for (A) PNPLA3 genotype, 
(B) TM6SF2 genotype, (C) 
HSD17B13 genotype and 
(D) “risk-allele” model (one 
point for each risk allele, e.g., 
PNPLA3 G-Allele, TM6SF2 
T-Allele, HSD17B13 T-Allele; 
groups “no risk alleles” and “1 
risk allele” have been subsumed 
into one group; to overcome 
potential effects of dilution by 




T-Allele carriage was classified 
as the “risk allele” [rather 
than TA-Allele carriage as 
“protective”] for the combined 
“risk-allele” model)
Univariable Multivariable
OR 95%CI p-value aOR 95%CI p-value
A
Age, per year 1.06 1.04–1.08  < 0.001 1.04 1.02–1.07  < 0.001
Sex, for being male 1.69 1.06–2.69 0.028 1.48 0.88–2.47 0.134
BMI, per unit 0.95 0.93–0.97  < 0.001 0.98 0.95–1.001 0.057
Diabetes, yes vs. no 3.91 2.42–6.31  < 0.001 3.36 1.98–5.69  < 0.001
PNPLA3 genotype
 C/C vs. C/G 1.39 0.82–2.34 0.224 1.51 0.85–2.65 0.155
 G/G 3.40 1.80–6.41  < 0.001 3.48 1.73–6.96  < 0.001
B
Age, per year – – – 1.04 1.02–1.06  < 0.001
Sex, for being male – – – 1.43 0.86–2.38 0.167
BMI, per unit – – – 0.97 0.95–0.99 0.025
Diabetes, yes vs. no – – – 3.45 2.05–5.82  < 0.001
TM6SF2 genotype
 C/C vs. T/– 1.82 1.05–3.15 0.033 1.99 1.10–3.62 0.023
C
Age, per year – – – 1.04 1.02–1.06 0.001
Sex, for being male – – – 1.44 0.86–2.38 0.160
BMI, per unit – – – 0.97 0.94–0.99 0.016
Diabetes, yes vs. no – – – 3.35 2.00–5.64  < 0.001
HSD17B13 genotype
 T/T vs. T/TA 0.81 0.49–1.33 0.406 0.86 0.50–1.48 0.596
 TA/TA 0.70 0.27–1.83 0.462 0.84 0.30–2.31 0.734
D
Age, per year – – – 1.04 1.02–1.06  < 0.001
Sex, for being male – – – 1.46 0.87–2.45 0.150
BMI, per unit – – – 0.98 0.95–1.001 0.060
Diabetes, yes vs. no – – – 3.44 2.02–5.85  < 0.001
Risk Alleles (Number of)
 0–1 Alleles vs. 2 2.31 1.04–5.17 0.041 2.21 0.96–5.12 0.064
 3 2.59 1.13–5.98 0.025 2.61 1.09–6.26 0.032
 4 4.54 1.78–11.56 0.002 4.34 1.61–11.66 0.004
 5 12.33 3.52–43.23  < 0.001 11.57 2.91–46.07 0.001
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well-known clinical risk factors for NASH resulted in better 
accuracy to non-invasively predict a NAS ≥ 5. Interestingly, 
an “allele-dose”-dependent effect was observed. In regard 
to presence of advanced fibrosis (≥ F3), both PNPLA3 and 
TM6SF2 models resulted in higher AUC than the baseline 
model; however, when significant fibrosis (≥ F2) was the 
endpoint of interest, only PNPLA3 status remained signifi-
cant. Nevertheless, while significant, those “addition” effects 
were only modest, highlighting the importance of standard 
clinical indices (age, diabetes, ALT, etc.) in the diagnostic 
work-up of NAFLD.
The effects of the PNPLA3-I148M variant on NAFLD/
NASH severity have been extensively studied [2, 15]. In 
previous studies, the rs738409 C > G variant increased the 
risk for hepatic steatosis, liver fibrosis/cirrhosis, as well as 
hepatocellular carcinoma in a wide spectrum of liver disease 
[16]. The PNPLA3 protein is highly expressed in the liver 
and has lipase activity towards triglycerides in hepatocytes 
and towards retinyl esters in hepatic stellate cells (HSC) 
[17]. The I148M mutation leads to loss of function resulting 
in hepatic fat and retinol retention [2]. PNPLA3 is required 
for human HSC activation and the I148M variant confers 
proinflammatory and profibrogenic properties to HSCs, 
leading to increased proliferation and migration, as well as 
production and release of cytokines and chemokines, which 
amplifies liver injury [17–19].
The pathophysiological role of the HSD17B13 variant 
and its protective effect on chronic liver disease is not yet 
fully understood and connecting the genetic association with 
a pathophysiological explanation requires elucidation. More-
over, the impact of HSD17B13 on the clinical course of liver 
disease could be stage dependent [20]. In general, 17BHSD 
are enzymes catalyzing the conversion between 17-keto and 
17-hydroxysteroids [21]. Fifteen HSDs have been identi-
fied and most of them play a role in regulation of biological 
activity of sex hormones [21], while HSD17B13 has been 
found to be merely involved in sex hormone metabolism 
[21, 22]. HSD17B13 is a hepatic retinol-dehydrogenase 
(RDH) involved in retinoid homeostasis [23]. Interestingly, 
hepatic expression of HSD17B13 was 5.9 times higher in 
NASH patients, although HSD17B13 genotype (rs6834314 
or rs72613567) did not affect hepatic expression [23].
Fig. 1  AUC for predicting NAS ≥ 5 applying a baseline model (BL; age, sex, BMI, diabetes, and ALT), b BL + PNPLA3, c BL + HSD17B13, d 
BL + TM6SF2, and e BL + PNPLA3 + HSD17B13; P-values: b, c, d vs. BL model; e vs. PNPLA3 model
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Fig. 2  AUC for predicting advanced fibrosis (≥ F3) using a baseline model (BL; age, sex, BMI, and diabetes), b BL + PNPLA3, c 
BL + HSD17B13 d, BL + TM6SF2, e BL + PNPLA3 + TM6SF2; P-values: b, c, and d vs. BL model; e vs. PNPLA model)
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Finally, TM6SF2 T/- allele carriage has been linked to 
disease severity in NAFLD [4], but interestingly, also to a 
lower risk for cardiovascular endpoints [24]. It is thought 
that the loss-of-function TM6SF2 T/- polymorphism leads 
to a higher liver triglyceride content in hepatocytes, while 
lowering circulating lipoproteins [25].
Whether the addition of genetic markers to well-known, 
clinically practicable, risk factors for NASH and advanced 
fibrosis facilitates risk stratification is yet unknown. In our 
study, the addition of both PNPLA3 and HSD17B13 geno-
types significantly improved the accuracy for the non-inva-
sive prediction of a NAS ≥ 5; however, the PNPLA3 model 
was most robust in the prediction of advanced and significant 
fibrosis when added to well-known clinical factors. Despite 
TM6SF2 showing improved AUCs compared to the baseline 
model, addition of TM6SF2 to the PNPLA3 “only” model 
did not significantly improve AUC and might, therefore, 
be uncalled-for. Moreover, we were able to demonstrate 
that throughout almost all histological markers of NAFLD 
(NAS including subgroups, fibrosis stage), disease sever-
ity increased in an “allele-dose”-dependent manner, as the 
severity of liver disease showed a stepwise increase with 
increasing number of risk alleles. Finally, wherever genetic 
testing is available, the potential applicability of our results 
in clinical practice should be high since patients from several 
(total of 7) centers were included in the study; hence, our 
cohort very well represents the average Central European 
NAFLD patient.
Nevertheless, when added on top of clinical risk factors, 
the improvements in AUC were moderate, suggesting that 
the clinical impact of genetic testing for assessment of dis-
ease severity may be limited. We would like to point out that 
in addition to other well-established risk factors, we also 
included ALT in the models for predicting NASH, which by 
itself is determined by the genetic background (as indicated 
by our and previous studies [26]) and thus, may reduce the 
impact of genetic factors if considered in the same model. 
However, since ALT is readily available in NAFLD patients, 
we decided to add it to the BL risk stratification model. Most 
importantly, we additionally evaluated whether addition of 
the respective genetic markers improved diagnostic accuracy 
for well-known non-invasive fibrosis scores such as FIB-4 
Table 3  Patient characteristics 
stratified by the number 
of PNPLA3, TM6SF2 and 
HSD17B13, risk alleles 
“(minimum: 0–1, maximum: 5; 
no patient was found with all 6 
“risk alleles”)
To overcome potential effects of dilution by combining risk polymorphisms [PNPLA3,TM6SF2] with 
protective polymorphisms [HSD17B13], HSD17B13 T-Allele carriage was classified as the “risk allele” 
[rather than TA-Allele carriage as “protective”] for the combined “risk-allele” model)
0–1 Alleles 2 Alleles 3 Alleles 4 Alleles 5 Alleles p-value
NAS, n (%)  < 0.001
 1–2 Points 79 (50.6%) 146 (52.3%) 75 (40.1%) 24 (36.4%) 4 (26.7%)
 3–4 Points 59 (37.8%) 71 (25.4%) 53 (28.3%) 14 (21.2%) 5 (33.3%)
 ≥ 5 points 18 (11.5%) 62 (22.2%) 59 (31.6%) 28 (42.4%) 6 (40%)
NAS, n (%)  < 0.001
 1–4 Points 138 (88.5%) 217 (77.8%) 128 (68.4%) 38 (57.6%) 9 (60%)
 ≥ 5 points 18 (11.5%) 62 (22.2%) 59 (31.6%) 28 (42.4%) 6 (40%)
NAS Steatosis, n (%) 0.026
 Grades 1–2 124 (79.5%) 217 (77.8%) 125 (66.8%) 45 (68.2%) 10 (66.7%)
 Grade 3 32 (20.5%) 62 (22.2%) 62 (33.2%) 21 (31.8%) 5 (33.3%)
NAS Inflammation, n (%) 0.143
 Grades 0–1 145 (92.9%) 259 (92.8%) 166 (88.8%) 57 (86.4%) 12 (80%)
 Grades 2–3 11 (7.1%) 20 (7.2%) 21 (11.2%) 9 (13.6%) 3 (20%)
NAS Ballooning, n (%) 0.002
 Grades 0–1 148 (94.9%) 240 (86%) 155 (82.9%) 52 (78.8%) 11 (73.3%)
 Grade 2 8 (5.1%) 39 (14%) 32 (17.1%) 14 (21.2%) 4 (26.7%)
Fibrosis, n (%)  < 0.001
 Grades 0–1 141 (90.4%) 233 (83.5%) 142 (75.9%) 48 (72.7%) 8 (53.3%)
 Grades 2–4 15 (9.6%) 46 (16.5%) 45 (24.1%) 18 (27.3%) 7 (46.7%)
Fibrosis, n (%)  < 0.001
 Grades 0–2 148 (94.9%) 248 (88.9%) 164 (87.7%) 53 (80.3%) 9 (60%)
 Grades 3–4 8 (5.1%) 31 (11.1%) 23 (12.3%) 13 (19.7%) 6 (40%)
Cirrhosis, n (%)  < 0.001
 No 153 (98.1%) 268 (96.1%) 179 (95.7%) 63 (95.5%) 11 (73.3%)
 Yes 3 (1.9%) 11 (3.9%) 8 (4.3%) 3 (4.5%) 4 (26.7%)
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or the NAFLD Fibrosis score (NFS) and could show that 
addition of PNPLA3 improved accuracy of only the NFS 
but not FIB-4 (Supplemental Figure S5 and S6). HSD17B13 
and TM6SF2 both did not show significant improvements of 
the respective AUCs. However, data regarding non-invasive 
fibrosis scores were not available in all patients and there-
fore, this finding still needs further evaluation.
Previous studies have looked into the concept of combin-
ing genetic risk factors and thereby improving their accu-
racy in predicting disease severity [27, 28]. Most recently, 
a combination of our proposed three genetic risk markers 
(PNPLA3, TM6SF2, HSD17B13) into a genetic risk score 
was shown to be associated with an increased risk for cirrho-
sis and HCC in the general population [29]—further empha-
sizing the clinical feasibility to utilize those combined mark-
ers also, and especially, in diagnosed NAFLD patients. Most 
recently, Anstee et al. found PNPLA3, TM6SF2, GCKR and 
HSD17B13 to have genome-wide significance on disease 
severity in NAFLD in an elegantly conducted GWAS study 
[30]. However, they did not assess the impact on clinical 
feasibility in non-invasively staging/predicting severity of 
NAFLD and did not implement a genetic risk score.
The major limitations of our study are the lack of 
non-invasive biomarkers and of longitudinal data. Also, 
Fig. 3  Distribution of risk alleles (PNPLA3 G, TM6SF2 T and HSD17B13 T-allele) across disease severity strata (a—NAS; b—Steatosis; c—
Inflammation; d—Ballooning; e—F ≥ 3; f—F ≤ 2)
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transient elastography or other non-invasive imaging 
parameters for NAFLD (e.g., magnetic resonance imag-
ing/elastography[MRI/MRE]) were not available in our 
patients. Especially in regard to imaging data, the ques-
tion whether combining genetic information with MRE 
data could improve its diagnostic accuracy might be worth 
studying and should be focus of future studies, especially 
since several studies have shown excellent AUCs for MRE 
to non-invasively predict fibrosis, not only in adults but also 
in children [31–33]. Moreover, information on MBOAT7 
genotype and other genetic factors was not available in 
most patients. MBOAT7 was, however, not associated with 
a more severe phenotype in the (small) subgroup of patients 
where data was available (data not shown). These limita-
tions may be outweighed by strengths of our study using 
liver biopsy (still the gold standard for fibrosis assessment) 
in a cohort of NAFLD patients from across Central Europe 
with information on genetic data on three important risk fac-
tors of NAFLD (PNPLA3, HSD17B13, and TM6SF2). An 
ideal study should explore the role of genetic risk factors in 
patients having in addition to liver biopsy a whole array of 
non-invasive markers. In clinical practice, outside of clinical 
trials, the population for non-invasive tests would be patients 
with only ultrasound and clinical data. Thus, the accuracy of 
our model should also be tested in this specific population.
In conclusion, in biopsy-proven NAFLD, PNPLA3-
I148M G/−, TM6SF2 T/− and HSD17B13 TA/− carriage 
are associated with severity of NAFLD in an “allele-dose”-
dependent fashion. The addition of genetic factors and their 
combinations into risk stratification models might provide 
incremental information and improve their predictive accu-
racy for severity of NAFLD (NAS ≥ 5) and/or advanced/
significant fibrosis on liver biopsy.
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